Search Results

Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.

• Authors : Masatoshi Kudo; Jassem, Jacek; Blanc, Jean Frederic

Subjects: LIVER cancer; SORAFENIB; VASCULAR endothelial growth factor antagonists

• Source: Lancet. 3/24/2018, Vol. 391 Issue 10126, p1163-1173. 11p. 3 Charts, 3 Graphs.

Record details

Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.

• Authors : Bruix, Jordi; Shukui Qin; Merle, Philippe

Subjects: REGORAFENIB; SORAFENIB; LIVER cancer

• Source: Lancet. 1/7/2017, Vol. 389 Issue 10064, p56-66. 11p. 1 Diagram, 2 Charts, 1 Graph.

Record details

Lenvatinib: can a non-inferiority trial change clinical practice?

• Authors : Reig, María; Bruix, Jordi

Subjects: CLINICAL drug trials; LIVER cancer; SORAFENIB

• Source: Lancet. 3/24/2018, Vol. 391 Issue 10126, p1123-1124. 2p. 1 Color Photograph.

Record details

Department of Error.

Subjects: PLACEBOS; LIVER cancer patients

• Source: Lancet. 1/7/2017, Vol. 389 Issue 10064, p36-36. 1p.

Record details

CYP2D6 genes and risk of liver cancer.

• Authors : Agundez, J.A.G.; Ledesma, M.C.

Subjects: *LIVER cancer; *CANCER risk factors

• Source: Lancet. 4/1/1995, Vol. 345 Issue 8953, p830. 2p. 2 Charts.

Record details